Sun Pharma Canada Inc. is focused on improving care by providing new innovative treatments in dermatologic diseases, specifically psoriasis and acne. Currently on the Canadian market, Sun Pharma launched PrILUMYA® (tildrakizumab injection), which is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Two pipeline products for the treatment of acne have been submitted to Health Canada for review: clascoterone cream (topical) to treat acne vulgaris; and an isotretinoin capsule for the treatment of severe recalcitrant nodular acne.

Sun Pharma first entered the Canadian market in 2015 with the purchase of Ranbaxy Laboratories Limited, and launched as a new corporate entity in 2020, with an emphasis on dermatology.

Sun Pharma also has a focus in ophthalmology, with PrCEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), which is indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye).
Taro Pharmaceuticals is the exclusive distributor of our generic products in Canada. Together, these complementary companies bring together bench strength in speciality, niche markets with a presence in the top 15 Canadian Gx products.

With global manufacturing across six continents, in more than 100 markets, Sun Pharma is investing in Canada by bringing high quality, affordable and innovative medicines to market. Our global strength in R&D with an unwavering commitment to quality ensures Sun Pharma will offer a wide range of affordable and innovative medicines for Canadians.